Comparative analysis of laboratory data of patients suffering from SARS-CoV-2-induced pneumonia and bacterial pneumonia

Abstract

Comparative analysis of laboratory data of 46 patients suffering from pneumonia caused by SARS-CoV-2 and 12 patients - pneumonia of bacterial etiology is given. It was established that in patients with COVID-19 compared to patients with bacterial pneumonia, the level of direct bilirubin is 84% more, and thrombocrit is three times more, which can indicate intravascular hemolysis and activation of the hemostasis system. Sex differences in laboratory indicators in patients with COVID-19, which go beyond the known limits of the physiological norm, were not detected. However, in men, hematocrit, hemoglobin, and plasma creatinine values were statistically higher than in women, but the amount of C-reactive protein in women was 5 times greater. However, these laboratory measures in COVID-19 have low prognostic significance. Therefore, conventional laboratory measures do not reveal clinic-critical differences in bacterial pneumonia and pneumonia caused by SARS-CoV-2. When conducting multifactorial analysis, it turned out that the laboratory indicators of patients suffering from bacterial pneumonia are not clustered and it is impossible to form predictor models from them. While laboratory indicators of patients suffering from pneumonia caused by COVID-19 form a directed pathogenetic response of the body as a whole, which causes multi-branch associated changes in homeostasis. Unfortunately, the amount of data available to us did not allow a qualitative discriminant analysis, which, with a very large amount of data, could lead to discriminant equations that are resistant to random “emissions.” This would allow, according to the available key individual laboratory indicators, to identify patients suffering from COVID-19 in the early stages already in the first hours of admission to the clinic.

Keywords

coronavirus / pneumonia / pathogenetic response / laboratory parameters / cytokines / multivariate analysis / intravascular hemolysis / coagulopathy

References

[1] Баклаушев, В.П. COVID-19. Этиология, патогенез, диагностика и лечение / В.П. Баклаушев, С.В. Кулемзин, А.А. Горчаков // Клин. прак. – 2020. – № 11. – С. 7–20.

[2] Временные рекомендации Международного общества специалистов по тромбозу и гемостазу (ISTH) по выявлению и коррекции коагулопатии у пациентов с COVID-19: дайджест // Атеротромбоз. – 2020. – № 1. – С. 6–8.

[3] Зайцев, А.А. Клинико-функциональная характеристика пациентов, перенесших новую коронавирусную инфекцию Сovid-19 / А.А. Зайцев [и др.] // Практ. пульмонолог. – 2020. – № 1. – С. 78–81.

[4] Крюков, Е.В. Алгоритмы ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре: метод. рекомендации / Е.В. Крюков [и др.]. – М.: ГВКГ им. Н.Н. Бурденко, 2020. – 16 с.

[5] Малинникова, Е.Ю. Новая коронавирусная инфекция. Сегодняшний взгляд на пандемию XXI века / Е.Ю. Малинникова // Инфекционные болезни: Новости. Мнения. Обучение. – 2020. – № 9. – С. 18–32.

[6] Проценко, Л. Умершая в больнице пожилая пациентка имела целый ряд хронических заболеваний / Л. Проценко // Росс. газета. – 2020. – № 59. – С. 5.

[7] Явелов, И.С. COVID–19: состояние системы гемостаза и особенности антитромботической терапии / И.С. Явелов, О.М. Драпкина // Кардиоваскулярная терапия и профилактика. – 2020. – № 19. – C. 2571.

[8] Andersen, K. G. The proximal origin of SARS–CoV–2 / K.G. Andersen, A. Rambaut, W.I. Lipkin // Nature medicine. – 2020. – № 26. – P. 450–452.

[9] Bloom, P. Liver Biochemistries in Hospitalized Patients With COVID–19 / P. Bloom / / American Association for the Study of Liver Diseases. – 2020.

[10] Chan, J. F. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person–to–person transmission: a study of a family cluster / J.F. Chan // Lancet. – 2020. – № 395. – P. 514–523.

[11] Chen, G. Clinical and immunologic features of severe and moderate coronavirus disease / G. Chen // J. Clin. Invest. – 2020. – № 130. – P. 2620–2629.

[12] Ciceri, F. Microvascular COVID19 lung vessels obstructive thromboinflammatory syndrome (MicroCLOTS): an atypical acute respiratory distress syndrome working hypothesis / F. Ciceri, L. Beretta, A.M. Scandroglio // Critical care and resuscitation: journal of the Australasian Academy of Critical Care Medicine – 2020. – № 22. – P. 95–97.

[13] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome–related coronavirus: classifying 2019–nCoV and naming it SARS–CoV–2 // Nat. Microbiol. – 2020. – № 5. – P. 536–544.

[14] Coronavirus disease 2019 (COVID–19) Situation Report // World Health Organisation – 2020. – № 26. – P. 1–4.

[15] Fehr, A. R. Coronaviruses: an overview of their replication and pathogenesis / A.R. Fehr, S. Perlman // Methods. Mol. Biol – 2020. – № 1282. – P. 1–23.

[16] Grobler, C. Covid–19: The Rollercoaster of Fibrin(Ogen), D–Dimer, Von Willebrand Factor, P–Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes / C. Grobler, S.C. Maphumulo, L.M. Grobbelaar // International journal of molecular sciences. – 2020. – № 21. – P. 5168.

[17] Guan, W. J. Clinical characteristics of coronavirus disease 2019 in China. / W.J. Guan // N. Engl. J. Med. – 2020. – № 382. – P. 1708–1720.

[18] Li, Q. Early transmission dynamics in Wuhan, China, of Novel Coronavirus–infected pneumonia / Q. Li // N. Engl. J. Med. – 2020. – № 382. – P. 1199–1207.

[19] Paliogiannis, P. Bilirubin levels in patients with mild and severe Covid–19: A pooled analysis / P. Paliogiannis, Z. Angelo // Liver international: official journal of the International Association for the Study of the Liver. – 2020. – № 40. – P. 1787 – 1788.

[20] Pence, B.D. Severe COVID–19 and aging: are monocytes the key? / B.D. Pence // GeroScience. – 2020. – № 42. – P. 1051–1061.

[21] Perlman, S. Coronaviruses post–SARS: update on replication and pathogenesis / S. Perlman, J. Netland // Nat Rev Microbiol. – 2009. – № 7. – P. 439–450.

[22] Phan, L. T. Importation and human–to–human transmission of a novel coronavirus in Vietnam / L.T. Phan // N. Engl. J. Med. – 2020. – № 382. – P. 872–874.

[23] Pung, R. Investigation of three clusters of COVID–19 in Singapore: implications for surveillance and response measures / R. Pung // Lancet. 2020. – № 395. – P. 1039–1046.

[24] Tang, N. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia / N. Tang, D. Li, X. Wang // Journal of thrombosis and haemostasis – 2020. – № 18. – P. 844–847.

[25] Tian, S. Pulmonary pathology of early phase 2019 novel coronavirus (COVID–19) pneumonia in two patients with lung cancer / S. Tian // Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. – 2020. – № 15. – P. 700–704.

[26] Xu, H. High expression of ACE2 receptor of 2019–nCoV on the epithelial cells of oral mucosa / H. Xu // International journal of oral science. – 2020. – № 12. – P. 8.

[27] Zhou, P. A pneumonia outbreak associated with a new coronavirus of probable bat origin. / P. Zhou // Nature. – 2020. – № 579. – P. 270–273.

RIGHTS & PERMISSIONS

Ismailov D.D., Isaev T.A., Shustov S.B., Sveklina T.S., Kozlov V.A.